-
ABOUT USThe company is a professional API manufacturer established and developed by Shijiazhuang No.4 Pharmaceutical Group to actively promote the development strategy of "API + preparation"
-
INNOVATIONDevelops fine, series, high-end API and innovative API intermediates with high added value through overcoming key technologies such as API synthesis to build variety competition advantages.
-
PRODUCTSWith the annual production 500MT of hydroxyethyl starch , 500MT of azithromycin , we are ranking in the API professional enterprises in Hebei Province and even in China .
-
RECRUITGuolong has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities
-
CONTACTAdhering to the "love the people with quality, formed the base with integrity" business philosophy, is committed to developing the domestic high-end market and the international market.
Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical has received approval for the active pharmaceutical ingredients of pentoxifylline, levonidazole, and ornidazole.
Category:
Time:2022-05-27
【概要描述】
Recently, three active pharmaceutical ingredients—pentoxifylline, levonidazole, and ornidazole—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, have been approved by the National Medical Products Administration and can now be officially used in marketed formulations.
During the Li Xia season, Shijiazhuang No.4 Pharmaceutical Group’s R&D and innovation efforts are entering a harvest period. Recently, three active pharmaceutical ingredients—pentoxifylline, levonidazole, and ornidazole—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang No.4 Pharmaceutical Group, have been approved by the National Medical Products Administration and can now be officially used in marketed formulations. Among these, pentoxifylline is the second domestic pharmaceutical company to receive approval, while levonidazole is the third.
It is reported that pentoxifylline preparations are primarily used for the treatment of peripheral vascular diseases and cerebral vascular insufficiency. Levonidazole and ornidazole preparations are mainly used for the treatment of various infections caused by susceptible anaerobic bacteria.
From January to May this year, Shijiazhuang Sihua Pharmaceutical Group has achieved remarkable success in scientific research and development. To date, a total of 16 new product projects have been approved, and 24 projects have been submitted one after another. Once these innovative achievements are approved and put into production, they will continuously inject new momentum into the company’s high-quality development, strongly promoting the integrated and sustained development of the company’s innovation chain and product chain. This will also play a significant role in boosting market vitality and facilitating the optimization and upgrading of the company’s product structure.
Keywords:
Recommended
Share to
SERVICE HOTLINE
Zip Code: 052165
Address: No.9 Xingye Street, Gaocheng District, Shijiazhuang City, Hebei Province
Mobile site
E code
Business license